STOCK TITAN

Corcept Therapeutics Inc - CORT STOCK NEWS

Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.

Corcept Therapeutics Inc. (NASDAQ: CORT) is a commercial-stage pharmaceutical company dedicated to the discovery and development of innovative medications that target the underlying effects of abnormal cortisol levels. Cortisol, a hormone essential for various bodily functions, can become dysregulated and contribute to a range of serious health conditions, including metabolic disorders, oncologic diseases, and neuropsychiatric illnesses. Corcept leverages its deep scientific expertise to address these challenges by developing drugs that modulate the glucocorticoid receptor (GR), a key mediator of cortisol's effects.

Core Business Areas

Corcept's business model is centered on the research, development, and commercialization of GR antagonists. The company’s flagship product, mifepristone, is approved for the treatment of hypercortisolism in certain conditions. Beyond this, Corcept has built an extensive pipeline of over 300 proprietary molecules, each designed to selectively block the GR without affecting the progesterone receptor. This specificity minimizes side effects and enhances therapeutic potential.

Addressing Unmet Medical Needs

Corcept’s innovative compounds are being evaluated in clinical trials for their ability to treat a variety of severe and life-threatening conditions. These include:

  • Hypercortisolism: A disorder characterized by excessive cortisol levels, often linked to Cushing's syndrome.
  • Oncologic Applications: Advanced ovarian cancer, prostate cancer, and other malignancies where cortisol plays a role in disease progression.
  • Neuropsychiatric Disorders: Conditions such as post-traumatic stress disorder (PTSD), mild cognitive impairment, and Alzheimer’s disease.
  • Metabolic Diseases: Non-alcoholic steatohepatitis (NASH) and other metabolic syndromes influenced by cortisol dysregulation.

Scientific Approach and Differentiation

What sets Corcept apart in the competitive pharmaceutical landscape is its singular focus on GR antagonism. Unlike traditional therapies that may broadly target hormonal pathways, Corcept’s compounds are designed to selectively block the GR, thereby mitigating the adverse effects of excess cortisol while preserving other hormonal functions. This approach is supported by extensive scientific literature and represents a promising avenue for treating diseases with high unmet medical needs.

Market Position and Growth Potential

Operating in the dynamic pharmaceutical industry, Corcept occupies a niche position as a pioneer in cortisol modulation therapies. Its focus on conditions with limited treatment options provides a strategic advantage, as does its robust pipeline of proprietary molecules. However, the company faces challenges typical of the sector, including regulatory approvals, competition from larger pharmaceutical firms, and the inherent risks of clinical trial outcomes. Despite these hurdles, Corcept’s unique scientific approach and targeted focus position it as a significant player in its field.

Commitment to Innovation

Corcept’s commitment to advancing medical science is evident in its investment in research and development. By exploring the role of cortisol in various diseases and developing compounds that address these mechanisms, the company aims to deliver transformative therapies that improve patient outcomes. Its strategic focus on unmet medical needs underscores its potential to make a lasting impact on the healthcare landscape.

Conclusion

Corcept Therapeutics Inc. exemplifies the intersection of scientific innovation and patient-focused care. Through its pioneering work in cortisol modulation, the company addresses some of the most pressing challenges in modern medicine. With a strong foundation in research, a growing pipeline of proprietary compounds, and a commitment to addressing unmet medical needs, Corcept is well-positioned to contribute significantly to the pharmaceutical industry.

Rhea-AI Summary
Corcept Therapeutics Incorporated completes enrollment in Phase 2 DAZALS trial for ALS patients, testing dazucorilant's efficacy in improving motor performance and quality of life. The study enrolled 249 patients and is expected to provide data by the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
-
Rhea-AI Summary
Corcept Therapeutics (CORT) completes enrollment in ROSELLA Phase 3 trial for ovarian cancer treatment with relacorilant and nab-paclitaxel, aiming to improve patient outcomes. The trial mirrors positive Phase 2 results, showing potential for relacorilant to enhance survival rates. Progression-free survival data expected by year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
-
Rhea-AI Summary
Corcept Therapeutics (CORT) completes enrollment in Phase 3 trial for relacorilant in patients with Cushing’s syndrome, targeting serious cardiometabolic comorbidities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
Rhea-AI Summary
Corcept Therapeutics Incorporated (CORT) reported strong financial results for Q4 2023 and full year 2023, with revenue increases of 31% and 20% respectively. They reiterated revenue guidance for 2024 at $600 - $630 million. The company's net income also showed significant growth. Clinical development programs are progressing well, with key milestones expected this year. Corcept is on-track to submit an NDA for relacorilant in Cushing’s syndrome and report data from various trials in Cushing’s syndrome, ovarian cancer, ALS, and more.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
-
Rhea-AI Summary
Corcept Therapeutics (CORT) announces preliminary results from the prevalence phase of its CATALYST study on Cushing’s syndrome in patients with difficult-to-control type 2 diabetes. The study, with 1,000 patients, reveals a 24% prevalence rate of hypercortisolism, higher than previously assumed. Final results to be presented at the American Diabetes Association’s 84th Scientific Sessions in June.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
-
Rhea-AI Summary
Corcept Therapeutics Incorporated (NASDAQ: CORT) will report Q4 and full-year 2023 financial results and provide a corporate update on February 15, 2024. A conference call is scheduled at 5:00 p.m. Eastern Time. Participants must register in advance to receive dial-in number and access PIN. A listen-only webcast and call replay will also be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
Rhea-AI Summary
Corcept Therapeutics Incorporated (NASDAQ: CORT) has appointed Roberto Vieira as President, Oncology. Vieira brings extensive experience in global commercialization of cancer medicines and building high-performing teams. He aims to lead Corcept's oncology division, initially focusing on ovarian cancer and expanding to other tumors, with a commitment to revolutionize cancer treatment through cortisol modulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
management
-
Rhea-AI Summary
Corcept Therapeutics Incorporated (CORT) reported preliminary, unaudited, financial results for the quarter- and year-ended December 31, 2023, provided 2024 revenue guidance, and announced a stock repurchase program. Fourth quarter revenue increased by 31% to $135.4 million, and full year 2023 revenue increased by 20% to $482.4 million. The company also announced a 2024 revenue guidance of $600 – $630 million and a $200 million stock repurchase program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.1%
Tags
buyback
-
Rhea-AI Summary
Corcept Therapeutics Incorporated (CORT) announces disappointing court decision regarding patent infringement by Teva Pharmaceuticals, plans to appeal vigorously
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.62%
Tags
none
Rhea-AI Summary
Corcept Therapeutics Incorporated (NASDAQ: CORT) reported a 22% increase in revenue for the third quarter of 2023, reaching $123.6 million. The company also raised its 2023 revenue guidance to $470 - $480 million. Net income per common share was $0.28 (diluted), compared to $0.30 in the same period last year. Corcept's cash and investments stood at $414.8 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.97%
Tags

FAQ

What is the current stock price of Corcept Therapeutics (CORT)?

The current stock price of Corcept Therapeutics (CORT) is $91.93 as of April 1, 2025.

What is the market cap of Corcept Therapeutics (CORT)?

The market cap of Corcept Therapeutics (CORT) is approximately 9.8B.

What does Corcept Therapeutics specialize in?

Corcept Therapeutics specializes in developing drugs that modulate the effects of cortisol to treat metabolic, oncologic, and neuropsychiatric disorders.

What is Corcept’s flagship product?

Corcept’s flagship product is mifepristone, approved for treating hypercortisolism in specific conditions.

What makes Corcept’s approach unique?

Corcept focuses on selective glucocorticoid receptor (GR) antagonism, which targets cortisol's effects without affecting other hormonal pathways.

What diseases are Corcept’s compounds being developed to treat?

Corcept’s compounds are being developed to treat hypercortisolism, advanced cancers, PTSD, Alzheimer’s disease, and metabolic disorders like NASH.

How does Corcept generate revenue?

Corcept generates revenue through the commercialization of its approved drugs and ongoing development of its proprietary pipeline.

What challenges does Corcept face in its industry?

Corcept faces challenges such as regulatory approvals, competition from larger pharmaceutical companies, and the risks inherent in clinical trials.

What is the significance of glucocorticoid receptor antagonism?

Glucocorticoid receptor antagonism helps mitigate the adverse effects of excess cortisol, offering potential treatments for various serious conditions.

What is Corcept’s competitive advantage?

Corcept’s competitive advantage lies in its focus on cortisol modulation and its extensive pipeline of proprietary GR antagonists.

What industries does Corcept Therapeutics operate in?

Corcept operates in the pharmaceutical and biotechnology industries, focusing on drug development for unmet medical needs.

How does Corcept contribute to addressing unmet medical needs?

Corcept develops innovative therapies targeting diseases with limited treatment options, such as hypercortisolism and advanced cancers.
Corcept Therapeutics Inc

Nasdaq:CORT

CORT Rankings

CORT Stock Data

9.78B
93.36M
11.44%
81.8%
15.21%
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY